Speaker: Gene Colice, MD, FCCP, Professor of Medicine, The George Washington University School of Medicine and Health Sciences, and Director of Pulmonary, Critical Care and Respiratory Services, Washington Hospital Center, Washington, D.C.

Company: Mylan Specialty L.P. (formerly Dey Pharma, L.P.)

12 to 12: 45 p.m.
ATS Industry Theater 2 (Beginning of aisle 70)
The Evolving Science of Asthma
This interactive presentation will detail the cells and molecular mediators of the respiratory immune system, how those components drive the pathology of asthma and how different therapeutic classes affect these interactions.

Speaker: W. Gerald Teague, MD, Professor of Pediatrics and Director of the Division of Pediatric Respiratory Medicine and Allergy, University of Virginia School of Medicine, Charlottesville, Va.

Company: Genentech USA, Inc., and Novartis Pharmaceuticals Corporation

12 to 12: 45 p.m.
ATS Industry Theater 3 (Behind Global Community)
The Clinical Profile of Daliresp™ (roflumilast)

Speaker: Dennis E. Doherty, MD, FCCP, Professor of Medicine, University of Kentucky, Lexington, Ky.

Company: Forest Laboratories, Inc.

12 to 12: 20 p.m.
ATS Mini Industry Theater (End of aisle 800)
Clinical Utility of FeNO
The presenter will review the literature and guidelines on exhaled nitric oxide and present case studies on its clinical utility

Speaker: Neal Jain, MD, FAAAAI, FAAP, Adjunct Faculty, Arizona State University College of Nursing and Health Innovation, Tempe, and Allergist/Immunologist, Maricopa Medical Center, Phoenix, and San Tan Allergy & Asthma, Gilbert

Company: Aerocrine

12:30 to 12: 50 p.m.
ATS Mini Industry Theater (End of aisle 800)
See Where We’ve Been and How We’ve Got Here: An Overview of Letairis 
Will be presented by two expert physicians in pulmonary arterial hypertension (PAH). Come and learn more about the overview of Letairis and the most recent changes to the product label.

Company: Gilead Sciences, Inc.

Monday
12 to 12: 45 p.m.
ATS Industry Theater 1 (End of aisle 70)
Adding on to Oral Therapy for PAH: What’s Next?
Join a panel of experts for the interactive discussion “Adding on to Oral Therapy for PAH: What’s Next?” This Industry Theater will explore how to help pulmonary arterial hypertension (PAH) patients who may need additional therapies. Topics: PAH disease background and treatment algorithm, prostacyclin MOA and efficacy, and inhaled prostacyclin.

Speaker: Steven Nathan, MD, Medical Director of the Lung Transplant Program and Director of the Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, Va.

Company: United Therapeutics

12 to 12: 45 p.m.
ATS Industry Theater 2 (Beginning of aisle 70)
COPD Update: A New Treatment Paradigm and a New Treatment Option
The Global Initiative for Chronic Obstructive Lung Disease (GOLD), American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), and European Respiratory Society (ERS) have updated their guidelines for the diagnosis, classification and treatment of COPD. Changes in these guidelines and their impact on clinical practice and patient care will be discussed. This Industry Theater will specifically focus on the placement of long-acting beta agonists within the revised treatment paradigms. Additionally, a newly approved long-acting ß2-agonist will be reviewed along with its placement within these guidelines. The case-based approach of the presentation will ensure clinical relevance.

Speakers/Faculty: Fernando Martinez, MD, Swift-McNear Professor of Pediatrics and Director of the Arizona Respiratory Center, University of Arizona College of Medicine, Tucson, and Reynold Panettieri Jr., MD, Robert L. Mayock and David A. Cooper Professor of Medicine, University of Pennsylvania Medical Center, Philadelphia

Company: Novartis Pharmaceuticals Corporation

12 to 12: 45 p.m.
ATS Industry Theater 3 (Behind Global Community)
Bronchial Thermoplasty: The Future Is Wide-Open!
Bronchial Thermoplasty (BT) is a non-pharmacologic procedure for the treatment of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long-acting ß-agonists. Come join us to learn more about this additional treatment option for long-lasting asthma control and the appropriate patients who may benefit from this procedure.

Speakers/Faculty: Neil Thomson, MD (Chairman), Professor of Respiratory Medicine, Gartnavel General Hospital, University of Glasgow, United Kingdom; Gerard Cox, MB, Director of the Division of Respirology and Associate Professor of Medicine, McMaster University, Hamilton, Ontario, Canada; Michael Wechsler, MD, Associate Director of the Brigham & Women’s Asthma Research Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.; Armin Ernst, MD, Chief of Pulmonary, Critical Care and Sleep Medicine, St. Elizabeth Medical Center, Boston, Mass.

Company: Boston Scientific

12:30 to 12: 50 p.m.
ATS Mini Industry Theater (End of aisle 800)
See Where We’ve Been and How We’ve Got Here: An Overview of Letairis 
Will be presented by two expert physicians in pulmonary arterial hypertension (PAH). Come and learn more about the overview of Letairis and the most recent changes to the product label.

Company: Gilead Sciences

Tuesday
12 to 12: 45 p.m.
ATS Industry Theater 2 (Beginning of aisle 70)
(International Attendees Only)
Reaching and Treating Small Airways: The Latest Evidence
This lecture will illustrate to the audience the most updated evidence in the detection of small airway impairment in clinical practice. Furthermore, data related to recent trials that assess the efficacy of small particle formulations that are able to reach and treat small airways will be presented.

Speakers: Nicola Scichilone, MD, Professor, University of Palermo, Italy, and Peter Barnes, MD, Professor of Thoracic Medicine, National Heart and Lung Institute, Head of Respiratory Medicine at Imperial College, and Honorary Consultant Physician at Royal Brompton Hospital, London

Company: Chiesi Farmaceutici SpA

12 to 12: 45 p.m.
ATS Industry Theater 3 (Behind Global Community)
It’s Time to Lead Change
Optiflow is one of the most exciting developments in respiratory medicine since the introduction of noninvasive ventilation nearly 20 years ago. Evolving clinical research suggests that Optiflow is more effective than traditional oxygen therapy and may in fact sanction an extended role in respiratory care.

Speakers: Peter C. Gay, MD (Co-chair), Professor and Consultant in Pulmonary, Critical Care and Sleep Medicine, Mayo Graduate School of Medicine, Rochester, Minn. He is a past president of the National Association for Medical Direction of Respiratory Care and is the recipient of the Sepracor Achievement Award for Excellence in Pulmonary Disease Management. Laurent Brochard, MD (Co-chair), Professor of Intensive Care Medicine, University Hospital of Geneva. He is currently Deputy Editor for the American Journal of Respiratory and Critical Care Medicine. He has also served on the Executive or Scientific Boards of several international societies, including the European Society of Intensive Care Medicine and the American Thoracic Society. Jean-Damien Ricard, MD, Professor of Intensive Care Medicine, Paris 7 – Denis Diderot University. He works in the Medical ICU of Louis Mourier Teaching Hospital, Colombes, just outside Paris. He is a member of the editorial board of the American Journal of Respiratory and Critical Care Medicine. Salvatore M. Maggiore, MD, PhD, Professor of Anesthesiology and Intensive Care, Catholic University of Sacred Heart, Rome. He works in the ICU of the Gemelli Teaching Hospital in Rome. He is currently Deputy Editor of Intensive Care Medicine and Chair of the Editorial & Publishing Committee of the European Society of Intensive Care Medicine. Steve G. Peters, MD, Professor and Consultant in both Pulmonary and Critical Care Medicine, Mayo Graduate School of Medicine, Rochester, Minn. He has served as Governor of the American College of Chest Physicians in Minnesota. He is a past President of the National Association for Medical Direction for Respiratory Care.

Company: Fisher & Paykel Healthcare